Malaria Vaccine: Pfs25-Pvs25
$353,966ZIAFY2011AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 39127706Paper 37100721Paper 37061547Paper 36808125Paper 35915227Paper 35895391Paper 33824913Paper 33741942Paper 32709983Paper 30061051Paper 29982707Paper 29522056Paper 28722588Paper 28719292Paper 27432885Paper 26590432Paper 26428458Paper 26324116Paper 26003037Paper 24737801Paper 20434549Paper 20080619Paper 18612426Paper 17190797
Abstract
In collaboration with Drs. John Robbins and Rachel Schneerson at the Laboratory of Developmental and Molecular Immunology of the NICHD, we have developed a candidate conjugate vaccine that consists of Pfs25-Pfs25 conjugates. The immune sera induced by the conjugate vaccine displayed ability to block parasite development in mosquitoes. An Investigational New Drug Application was filed with FDA, intending a Phase 1 trial to test the safety, immunogenicity, and ex-vivo transmission blocking activity in humans. In response to FDAs comment, additional animal studies were conducted to evaluate the safety in animals.
View original record on NIH RePORTER →